复方青黛丸联合复方氨肽素治疗银屑病的临床研究

Clinical study of Compound Qingdai Pill Combined with Compound Antaisu in Treatment of Psoriasis

目的:观察复方青黛丸联合复方氨肽素治疗进行期寻常型银屑病的疗效和安全性。方法:选取本科2011年10月-2013年11月收治的101例进行期寻常型银屑病患者,按照随机数字表法将其分为联合治疗组51例和对照组50例,联合治疗组采用内服复方青黛丸、复方氨肽素片,外用复方氟米松软膏治疗;对照组除不用复方青黛丸外,其余用药均与治疗组相同。连续8周为一疗程,治疗期间每周患者复诊1次,观察比较两组患者的临床疗效及不良反应情况。结果:治疗1个疗程后,联合治疗组的总有效率80.39%(41/51)明显高于对照组的60.00%(30/50),差异有统计学意义(字2=5.028,P<0.05)。联合治疗组的平均起效时间(10.7±3.3)d明显短于对照组的(13.9±5.4)d,差异有统计学意义(t=3.601,P<0.05)。而两组的不良反应发生率无明显差异(P>0.05)。结论:两药联合治疗进行期寻常型银屑病的疗效显著,不良反应少,安全性高,值得临床推广。

Objective：To observe the curative effect and safety of compound Qingdai pill combined with compound antaisu in treatment of active stage psoriasis vulgaris.Method：101 patients with active stage psoriasis vulgaris in our department from October 2011 to November 2013 were selected,they were divided into the combined treatment group for 51 cases and the control group for 50 cases according to the random number table method.The combined treatment group was given compound Qingdai pill combined with compound Amino-polypeptide tablets orally,compound Flumetasone Ointment for external use.The control group was given the same drug as the treatment group,except for compound Qingdai pill.For 8 weeks as 1 course of treatment,during treatment with 1 times a week to visit,the clinical effect and adverse reaction between the two groups were observed and compared.Result：After 1 course,the total effective rate of combined treatment group was 80.39%（41/51）,it was significantly higher than 60.00%（30/50）of control group,the difference was statistically significant（ χ^2=5.028,P〈0.05）.The average onset time of combined treatment group was（10.7±3.3）d,it was significantly shorter than（13.9±5.4）d of control group,the difference was statistically significant（t=3.601,P〈0.05）.There was no significant difference in the incidence of adverse reaction between two groups（P〉0.05）.Conclusion：The two drugs in the treatment of psoriasis vulgaris has obvious curative effect,less adverse reaction,high security,is worthy of clinical promotion.